Kanjana S Perera1, Mukul Sharma2, Stuart J Connolly2, Jia Wang2, Michael R Gold3, Stefan H Hohnloser4, Chu Pak Lau5, Isabelle C Van Gelder6, Carlos Morillo2, Alessandro Capucci7, Carsten W Israel4, Gluca Botto7, Jeffery S Healey2. 1. Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. Electronic address: kanjana.perera@phri.ca. 2. Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. 3. Medical University of South Carolina, Charleston, SC. 4. J.W. Goethe University, Frankfurt, Germany. 5. Queen Mary Hospital, Department of Medicine, University of Hong Kong, Hong Kong, China. 6. Department of Cardiology, Thoraxcenter, University of Groningen University Medical Center Groningen, Groningen, the Netherlands. 7. Clinica di Cardiologia, Università Politecnica delle Marche, Ancona, Italy.
Abstract
BACKGROUND: The Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) demonstrated that subclinical atrial fibrillation (SCAF) was associated with a 2.5-fold increased risk of stroke. However, the absolute stroke rate was only 1.7% per year and fewer than 20% patients with stroke had SCAF in the preceding 30 days. This raises the possibility that SCAF is merely a risk marker for stroke rather than the cause. Systematic characterization of stroke subtypes among patients with SCAF would help clarify this issue. METHODS: All ischemic strokes that occurred in the ASSERT trial were blindly adjudicated by stroke neurologists, classified as cortical versus subcortical, and subtyped using modified TOAST criteria. Stroke severity was measured using the modified Rankin Score. RESULTS: Of the 44 participants who had an ischemic stroke, 14 had SCAF before stroke. Among patients with SCAF who had stroke, 57% of strokes (n = 8) were judged to be cardioembolic, 36% to be lacunar (n = 5), and 7% (n = 1) to be large artery disease. However, of 5 patients who had SCAF detected within 30 days before their index stroke, 4 patients had a cardioembolic stroke. The average duration of SCAF in these 4 patients was 6.0 ± 6.1 h/d. The modified Rankin score at 30 days was similar between patients with (2.7 ± 2.3) and without SCAF (2.3 ± 2.0; P = .68). CONCLUSIONS: In patients with SCAF and stroke, SCAF seems probably causal in many cases; however, in more than 40%, it seems to be acting only as a risk marker.
RCT Entities:
BACKGROUND: The Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) demonstrated that subclinical atrial fibrillation (SCAF) was associated with a 2.5-fold increased risk of stroke. However, the absolute stroke rate was only 1.7% per year and fewer than 20% patients with stroke had SCAF in the preceding 30 days. This raises the possibility that SCAF is merely a risk marker for stroke rather than the cause. Systematic characterization of stroke subtypes among patients with SCAF would help clarify this issue. METHODS: All ischemic strokes that occurred in the ASSERT trial were blindly adjudicated by stroke neurologists, classified as cortical versus subcortical, and subtyped using modified TOAST criteria. Stroke severity was measured using the modified Rankin Score. RESULTS: Of the 44 participants who had an ischemic stroke, 14 had SCAF before stroke. Among patients with SCAF who had stroke, 57% of strokes (n = 8) were judged to be cardioembolic, 36% to be lacunar (n = 5), and 7% (n = 1) to be large artery disease. However, of 5 patients who had SCAF detected within 30 days before their index stroke, 4 patients had a cardioembolic stroke. The average duration of SCAF in these 4 patients was 6.0 ± 6.1 h/d. The modified Rankin score at 30 days was similar between patients with (2.7 ± 2.3) and without SCAF (2.3 ± 2.0; P = .68). CONCLUSIONS: In patients with SCAF and stroke, SCAF seems probably causal in many cases; however, in more than 40%, it seems to be acting only as a risk marker.
Authors: Jeff S Healey; David J Gladstone; Balakumar Swaminathan; Jens Eckstein; Hardi Mundl; Andrew E Epstein; Karl Georg Haeusler; Robert Mikulik; Scott E Kasner; Danilo Toni; Antonio Arauz; George Ntaios; Graeme J Hankey; Kanjana Perera; Jorge Pagola; Ashfaq Shuaib; Helmi Lutsep; Xiaomeng Yang; Shinichiro Uchiyama; Matthias Endres; Shelagh B Coutts; Michal Karlinski; Anna Czlonkowska; Carlos A Molina; Gustavo Santo; Scott D Berkowitz; Robert G Hart; Stuart J Connolly Journal: JAMA Neurol Date: 2019-07-01 Impact factor: 18.302
Authors: Klaus K Witte; Georgios Tsivgoulis; Matthew R Reynolds; Stelios I Tsintzos; Simon Eggington; Eleni Ismyrloglou; Julie Lyon; Marianne Huynh; Marta Egea; Bonnie de Brouwer; Paul D Ziegler; Noreli Franco; Rashmi Joglekar; Sarah C Rosemas; Shufeng Liu; Vincent Thijs Journal: BMC Cardiovasc Disord Date: 2021-03-31 Impact factor: 2.298
Authors: Takumi Toya; Jaskanwal D Sara; Eugene L Scharf; Ali Ahmad; Valentina Nardi; Ilke Ozcan; Lilach O Lerman; Amir Lerman Journal: J Am Heart Assoc Date: 2021-10-08 Impact factor: 5.501